PureTech Health PLC Result of AGM (1066A)

TIDMPRTC

RNS Number : 1066A

PureTech Health PLC

27 May 2021

27 May 2021

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech Health" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

 
        Resolutions              For          %       Against       %      Withheld       Total 
                                                                                          votes 
                                                                                           cast 
 001. To approve 
  the Company's 
  Annual Report 
  and Accounts for 
  year ended 31 
  December 2020              225,240,798   100.00%     10,921     0.00%     273,846    225,251,719 
                            ------------  --------  -----------  -------  ----------  ------------ 
 002. To approve 
  the Directors' 
  Remuneration Report        200,319,991   89.74%    22,895,826   10.26%   2,309,748   223,215,817 
                            ------------  --------  -----------  -------  ----------  ------------ 
 003. To approve 
  the Directors' 
  Remuneration Policy        187,285,809   83.90%    35,930,008   16.10%   2,309,748   223,215,817 
                            ------------  --------  -----------  -------  ----------  ------------ 
 004. To elect 
  Dr. Raju Kucherlapati 
  as a director              222,659,203   98.73%    2,865,525    1.27%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 005. To elect 
  Dr. John LaMattina 
  as a director              218,438,727   96.86%    7,086,001    3.14%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 006. To elect 
  Ms. Kiran Mazumdar-Shaw 
  as a director              189,257,653   84.32%    35,193,037   15.68%   1,074,875   224,450,690 
                            ------------  --------  -----------  -------  ----------  ------------ 
 007. To elect 
  Dame Marjorie 
  Scardino as a 
  director                   222,228,072   98.54%    3,296,656    1.46%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 008. To elect 
  Mr. Christopher 
  Viehbacher as 
  a director                 199,985,210   88.68%    25,539,518   11.32%      837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 009. To elect 
  Dr. Robert Langer 
  as a director              218,164,180   96.74%    7,360,548    3.26%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 010. To elect 
  Ms. Daphne Zohar 
  as a director              225,474,510   99.98%      50,218     0.02%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 011. To elect 
  Dr. Bharatt Chowrira 
  as a director              225,473,830   99.98%      50,898     0.02%       837      225,524,728 
                            ------------  --------  -----------  -------  ----------  ------------ 
 012. To reappoint 
  KPMG LLP as Auditors 
  of the Company             225,291,096   99.90%     234,469     0.10%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 013. To authorize 
  the Audit Committee 
  to determine the 
  Auditors' remuneration     225,483,695   99.98%      41,870     0.02%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 014. To authorize 
  the allotment 
  of shares                  221,538,872   98.23%    3,986,693    1.77%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 015. To disapply 
  pre-emption rights         225,102,915   99.81%     422,650     0.19%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 016. To further 
  disapply pre-emption 
  rights for acquisitions 
  and specified 
  capital investments.       215,316,258   95.47%    10,209,307   4.53%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 017. To authorize 
  market purchase 
  of own shares              225,235,005   99.89%     258,692     0.11%     31,868     225,493,697 
                            ------------  --------  -----------  -------  ----------  ------------ 
 018. To authorize 
  general meetings 
  to be called on 
  not less than 
  14 clear days' 
  notice                     222,063,258   98.46%    3,462,307    1.54%        0       225,525,565 
                            ------------  --------  -----------  -------  ----------  ------------ 
 

Notes:

(1) A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

(2) As at May 27, 2021 the number of issued shares in the Company was 286,018,538 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

(3) The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech ' s Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report on Form 20-F. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company ' s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to , those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 
 Contact: 
  Investors 
 Allison Mead Talbot 
  [phone] 
  [e-mail] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKOBKOBKDFPB

(END) Dow Jones Newswires

May 27, 2021 13:16 ET (17:16 GMT)